Trending...
- Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
- Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
- BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
Cures Within Reach's Virtual Pitch Event on October 6 Features Four Clinical Repurposing Trials
CHICAGO - illiNews -- Cures Within Reach, a leading global nonprofit focused on repurposing research as a fast track to impacting patients, is holding CureAccelerator Live! for Diversity, Equity & Inclusion (DEI), its unique philanthropic pitch competition, virtually on October 6, 2022. The event this year is being held in collaboration with DIA and its Advancing Diversity, Equity, and Inclusion Across Life Sciences R&D Meeting on October 6 – 7, 2022.
Researchers and clinicians from 4 institutions across the US will present their clinical repurposing research trials to community members representing industry, research, medicine, philanthropy and patient groups. The winning trial will be selected by attendees to receive a grant that supports a $70,000 clinical trial.
The 4 finalists presenting their clinical trials are:
More on illi News
DIA is excited to partner with Cures Within Reach in October on our shared interest in expanding clinical trials for Diversity, Equity, and Inclusion. "Our 2-day meeting, Advancing Diversity, Equity, and Inclusion Across Life Sciences R&D Meeting, will lead the way in sharing knowledge and fostering coalitions to build greater diversity, equity, and inclusion efforts in the life sciences R&D field," said Tamei Elliott, Senior Manager of Scientific Programs for DIA and Chair of the meeting. "Providing our attendees with the opportunity to participate in and vote on funding of DEI-focused clinical trials through the CureAccelerator Live! event will drive home the tangible difference that each one of us can make."
DIA (Drug Information Association) is a global, member-driven organization mobilizing life sciences and health care professionals. All attendees of DIA's meeting can attend Cures Within Reach's CureAccelerator Live! event. For more information, agenda and registration, visit https://www.diaglobal.org/en/conference-listing... - showcontent (https://www.diaglobal.org/en/conference-listing/meetings/2022/10/advancing-diversity-equity-and-inclusion-across-life-sciences-r-d-meeting#showcontent). More information on the competition finalists and to register just to join CureAccelerator Live! for DEI is at: https://bit.ly/cwrcal22.
More on illi News
Funding for Cures Within Reach's DEI efforts, including clinical trials to impact health disparities and/or led by racial/ethnic minority researchers, comes from its philanthropic and industry partners: Takeda Pharmaceuticals' Center for Health Equity, Searle Funds at The Chicago Community Trust, Adtalem Global Education Foundation, Burroughs Wellcome Fund, Horizon Therapeutics, Walder Foundation and others.
About Cures Within Reach
Cures Within Reach (CWR) is a US-based philanthropic leader leveraging the speed, safety and cost-effectiveness of testing approved treatments for new indications to improve patient quality and length of life: driving more treatments to more patients more quickly. CWR focuses on first-in-human or proof-of-concept clinical repurposing trials that catalyze the follow-on funding needed to continue the research – providing seed funds and building evidence for publication and follow-on trials allowing clinicians to make their own decisions with their patients (called off-label use), or for regulatory approval by the FDA or other agencies. CWR's 2022 initiatives include Diversity, Equity & Inclusion, impacting Veterans' Issues and Pediatrics, as well as several disease-specific efforts. CWR currently has a global portfolio of 39 ongoing trials at 32 institutions in 29 diseases in 8 countries. Visit cureswithinreach.org (http://www.cureswithinreach.org/).
Researchers and clinicians from 4 institutions across the US will present their clinical repurposing research trials to community members representing industry, research, medicine, philanthropy and patient groups. The winning trial will be selected by attendees to receive a grant that supports a $70,000 clinical trial.
The 4 finalists presenting their clinical trials are:
- Edilberto Amorim, MD of University of California, San Francisco: Testing the epilepsy drug perampanel to prevent seizures after cardiac arrest
- Yohannes Ghebre, PhD of Baylor College of Medicine: A new use of the antacid drug esomeprazole to treat morphea, a chronic connective tissue disease
- Sheldon Holder, MD, PhD of Brown University: Repurposing the prostate cancer drug degarelix to treat bladder cancer
- Natasha Shur, MD of Children's National Research Institute: Using steroids to improve outcomes in rhabdomyolysis in pediatric patients
More on illi News
- Entyre Solutions Launches to Support Senior Living Operators
- Jungbunzlauer Launches New TayaGel® LA at IFT First 2025, strengthening its texturants portfolio USA - English USA - English USA - Français Japan - Japanese USA - Deutsch
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Eliza Nevius Reimagines a Classic with a Dark, Witty Twist in The Key to Wonderland
DIA is excited to partner with Cures Within Reach in October on our shared interest in expanding clinical trials for Diversity, Equity, and Inclusion. "Our 2-day meeting, Advancing Diversity, Equity, and Inclusion Across Life Sciences R&D Meeting, will lead the way in sharing knowledge and fostering coalitions to build greater diversity, equity, and inclusion efforts in the life sciences R&D field," said Tamei Elliott, Senior Manager of Scientific Programs for DIA and Chair of the meeting. "Providing our attendees with the opportunity to participate in and vote on funding of DEI-focused clinical trials through the CureAccelerator Live! event will drive home the tangible difference that each one of us can make."
DIA (Drug Information Association) is a global, member-driven organization mobilizing life sciences and health care professionals. All attendees of DIA's meeting can attend Cures Within Reach's CureAccelerator Live! event. For more information, agenda and registration, visit https://www.diaglobal.org/en/conference-listing... - showcontent (https://www.diaglobal.org/en/conference-listing/meetings/2022/10/advancing-diversity-equity-and-inclusion-across-life-sciences-r-d-meeting#showcontent). More information on the competition finalists and to register just to join CureAccelerator Live! for DEI is at: https://bit.ly/cwrcal22.
More on illi News
- Naperville Police Initiate Death Investigation
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- Mayor Johnson Appoints Era Patterson As Executive Director Of The Chicago Office Of Public Safety Administration
- Chicago: Mayor Brandon Johnson Attends Groundbreaking For Jigzibik Affordable Housing Complex
- The Sessions Studios Secures $300 Million Commitment to Launch World-Class Studio and 15-Film Global Slate
Funding for Cures Within Reach's DEI efforts, including clinical trials to impact health disparities and/or led by racial/ethnic minority researchers, comes from its philanthropic and industry partners: Takeda Pharmaceuticals' Center for Health Equity, Searle Funds at The Chicago Community Trust, Adtalem Global Education Foundation, Burroughs Wellcome Fund, Horizon Therapeutics, Walder Foundation and others.
About Cures Within Reach
Cures Within Reach (CWR) is a US-based philanthropic leader leveraging the speed, safety and cost-effectiveness of testing approved treatments for new indications to improve patient quality and length of life: driving more treatments to more patients more quickly. CWR focuses on first-in-human or proof-of-concept clinical repurposing trials that catalyze the follow-on funding needed to continue the research – providing seed funds and building evidence for publication and follow-on trials allowing clinicians to make their own decisions with their patients (called off-label use), or for regulatory approval by the FDA or other agencies. CWR's 2022 initiatives include Diversity, Equity & Inclusion, impacting Veterans' Issues and Pediatrics, as well as several disease-specific efforts. CWR currently has a global portfolio of 39 ongoing trials at 32 institutions in 29 diseases in 8 countries. Visit cureswithinreach.org (http://www.cureswithinreach.org/).
Source: Cures Within Reach
0 Comments
Latest on illi News
- Echo Global Logistics Wins Inbound Logistics' #1 3PL for Ninth Year in a Row
- DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
- Whirlpool Brand and Premier Lacrosse League Announce Chicago River Stunt in Celebration of the League's Highly-Anticipated Return
- Assent Expands Executive Team to Accelerate Global Growth & Innovation
- The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
- Jungbunzlauer Showcases Bioavailable Mineral Innovations for Gummies at IFT FIRST 2025
- Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
- Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft
- Revenue Valve Tells Why Visual Storytelling Is the Secret Weapon for Healthcare Nonprofits
- Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
- Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
- Digi 995 Expands Its Universe: All Three Novels Now Available in Paperback Worldwide
- Chicago: Mayor Brandon Johnson on Track to Hit Summer Youth Employment Goal with Almost 29,000 Young People Hired for Third Consecutive Year of Expanded Opportunities
- $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co
- Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
- Radarsign Tackles Intersection Safety with Launch of Grid-Free Solar LED Stop Sign
- Miami Real Estate Agent Drastically Increases Interest In Homes
- Adostics & Genmega Announce the Introduction of A-POD
- LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
- Digi 995 Audiobooks Officially Released: Fans Can Now Listen to the Complete Trilogy